Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Infigratinib→

Infigratinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
872511-34-7
Molecular formula
C26H31Cl2N7O3
Molecular weight
560.48 g/mol
Drug class
Fibroblast growth factor receptor (FGFR) 1-3 tyrosine kinase inhibitortargeted antineoplastic (withdrawn US indication)
Mechanism of action
Inhibits FGFR1, FGFR2 and FGFR3 tyrosine kinase activity, reducing downstream signalling in tumours driven by susceptible FGFR alterations.
Indications / reported uses
  • Historical US indication: treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement. US approval of Truseltiq was withdrawn 16 May 2024; do not list as a current US-authorised treatment.

Sources: US FDA — Withdrawn cancer accelerated approvals · Federal Register — Withdrawal of Truseltiq approval · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Infigratinib Environmental Risk Assessment (ERA) (the Infigratinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.